Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11839654 Combination therapy

Patent 11839654 was granted and assigned to Eli Lilly and Company on December, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Eli Lilly
Eli Lilly
0
Date Filed
January 5, 2021
0
Date of Patent
December 12, 2023
0
Patent Applicant
Eli Lilly
Eli Lilly
0
Patent Application Number
17141667
0
Patent Citations
‌
US Patent 7446180 Conformationally abnormal forms of tau proteins and specific antibodies thereto
0
‌
US Patent 7161060 Transgenic mice comprising a genomic human tau transgene
0
‌
US Patent 7238788 Antibodies to phosphorylated tau, methods of making and methods of use
0
‌
US Patent 7442516 Antibody specific to central nervous system tau protein
0
‌
US Patent 8940272 Human anti-tau antibodies
0
‌
US Patent 8980270 Methods of treating a tauopathy
0
‌
US Patent 8980271 Methods of treating a tauopathy
0
‌
US Patent 9051367 Methods of treating a tauopathy
0
‌
US Patent 9120781 Selective glycosidase inhibitors and uses thereof
0
‌
US Patent 9139643 Immunotherapy for clearing pathological tau conformers
0
•••
Patent Inventor Names
Michael Carl Irizarry
0
Mansuo Lu Hayashi
0
Hugh Nuthall
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11839654
0
Patent Primary Examiner
‌
Kimberly Ballard
0
CPC Code
‌
A61K 2300/00
0
‌
A61K 2039/505
0
‌
A61K 39/3955
0
‌
C07D 417/14
0
‌
A61K 31/454
0
‌
A61P 25/28
0

Find more entities like US Patent 11839654 Combination therapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.